1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002. 288:321–333.
2. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003. 290:1729–1738.
3. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004. 291:47–53.
4. Nelson HD. Assessing benefits and harms of hormone replacement therapy: clinical applications. JAMA. 2002. 288:882–884.
5. Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med. 2003. 348:579–580.
6. Pines A, Sturdee DW, Birkhauser MH, Schneider HP, Gambacciani M, Panay N. IMS updated recommendations on postmenopausal hormone therapy. Climacteric. 2007. 10:181–194.
7. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007. 297:1465–1477.
8. Korea National Statistics Office. Statistics for the elderly. 2007. Daejeon: Korea National Statistics Office.
9. Korea National Statistics Office. Statistics for the future population. 2006. Daejeon: Korea National Statistics Office.
10. Korea National Statistics Office. International Marketing Service. The statistics of medicine. 2009. Daejeon: Korea National Statistics Office.
11. Panay N, Fenton A. HRT: does the dose matter? Climacteric. 2008. 11:177–178.
12. Birkhauser MH, Reinecke I. Current trends in hormone replacement therapy: perceptions and usage. Climacteric. 2008. 11:192–200.
13. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric. 2007. 10:120–131.
14. Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev. 2004. 25:45–71.
15. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005. 51:21–28.
16. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009. 10:135–146.
17. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008. 359:697–708.
18. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Soderqvist G, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002. 186:717–722.
19. Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007. 92:911–918.
20. Huang KE, Baber R. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric. 2010. 13:317–327.